Bashar Alasad, MD
Hematology & Oncology · Oklahoma City, OKNPI 1215988803
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,902 of the $2,224 with a category attached, or 85.5%. It is spread thinly across 33 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in OK, where the typical reported total is $2,658.
Across 107 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$296
- Novartis$182
- Johnson & Johnson$152
- Sanofi$127
- E.r. Squibb & Sons, L.L.C.$117
- Bristol Myers Squibb$108
- plus $1K from 27 others
Across 45 payments — averaging $4972.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$129K
- Argenx US, Inc.$58K
- Incyte Corporation$10K
- E.r. Squibb & Sons, L.L.C.$10K
- Bristol Myers Squibb$10K
- Coherus Oncology, Inc.$7K
- plus $796 from 2 others
What the payments were for
- Food & beverage$1,90285%
- Education$32315%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $296 |
| Novartis | 8 | $182 |
| Johnson & Johnson | 4 | $152 |
| Sanofi | 6 | $127 |
| E.r. Squibb & Sons, L.L.C. | 7 | $117 |
| Bristol Myers Squibb | 6 | $108 |
| Gilead | 6 | $103 |
| Merck | 6 | $102 |
| Genentech USA, Inc. | 5 | $101 |
| Sobi, Inc | 4 | $94 |
| Intuitive Surgical | 1 | $74 |
| Daiichi Sankyo Inc. | 3 | $74 |
| AbbVie | 3 | $71 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Incyte Corporation | 3 | $55 |
| AstraZeneca(2 entities) | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Astellas Pharma US Inc | 2 | $45 |
| Seagen Inc. | 2 | $39 |
| Eisai Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| Array Biopharma Inc | 1 | $26 |
| Acrotech Biopharma Inc. | 2 | $26 |
| Myovant Sciences Inc. | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Exelixis Inc. | 1 | $19 |
| Geron Corporation | 1 | $18 |
| CTI Biopharma Corp. | 1 | $16 |
| Bayer | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$109
How this compares
$2,224 in reported general payments places this provider in the 45th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 70 | $1,159,696 |
| RevlimidLenalidomide | 43 | $687,850 |
| ErleadaApalutamide | 23 | $346,672 |
| ImbruvicaIbrutinib | 23 | $304,280 |
| GleevecImatinib Mesylate | 14 | $281,439 |
| LynparzaOlaparib | 13 | $203,654 |
| Abiraterone Acetate | 54 | $151,773 |
| XtandiEnzalutamide | 11 | $139,432 |
| TavalisseFostamatinib Disodium | 13 | $95,515 |
| EliquisApixaban | 60 | $52,418 |
| Xtampza ErOxycodone Myristate | 24 | $23,904 |
| CreonLipase/Protease/Amylase | 12 | $3,014 |
| Anastrozole | 145 | $2,852 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 147 | $2,796 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 83 | $2,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $55 | $1,159,69670 claims |
| Bristol Myers SquibbRevlimid | $108 | $687,85043 claims |
| Johnson & JohnsonErleada | $152 | $346,67223 claims |
| NovartisGleevec | $182 | $281,43914 claims |
| AstraZenecaLynparza | $53 | $203,65413 claims |
| Astellas Pharma US IncXtandi | $45 | $139,43211 claims |
| PfizerEliquis | $296 | $52,41860 claims |
| AbbVieCreon | $71 | $3,01412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.